Currently, this pathology is at the center of attention, not only because of the advances in molecular imaging for its early diagnosis but also because of the recent approval of new therapeutic strategies aimed at transthyretin stabilizers in TTR-CA and chemotherapy in LC-CA. Here, TTR is linked to laryngotracheoesophageal cleft.